population health

Research in Review

Risk-Adapted Therapy Reduces Treatment Toxicity for Patients With Hodgkin Lymphoma

05/19/2017

JCP Editors

A combined chemotherapy approach may eliminate the toxic effects of radiation therapy in children and young adults with Hodgkin lymphoma, according to early results of a study that will be presented at the 2017 ASCO...

A...

05/19/2017

Journal of Clinical Pathways

Research in Review

Immune Checkpoint Inhibitors May Increase Response to CAR-T Therapy in ALL

05/19/2017

JCP Editors

Pembrolizumab improves response to chimeric antigen receptor (CAR) T-cell treatments in pediatric patients with B-cell relapsed acute lymphoblastic leukemia (ALL), according to research that will be presented at...

...

05/19/2017

Journal of Clinical Pathways

Research in Review

New Therapy May Effectively Treat Rare B-Cell Malignancy

05/18/2017

JCP Editors

A new treatment for a rare B-cell malignancy provided an objective response rate of 41% in a clinical trial, published in Blood (published online May 10, 2017; doi:10.1182/blood-2016-12-758383). ----- Related...

A new...

05/18/2017

Journal of Clinical Pathways

Research in Review

Surveillance More Effective Than Surgery for Patients With Rectal Cancer After First-Line Care

05/09/2017

JCP Editors

Patients with rectal cancer who undergo first-line chemotherapy and radiation have lower risk of recurrence and higher rates of survival regardless of whether they choose to have surgery, according to a study...

...

05/09/2017

Journal of Clinical Pathways

Research in Review

Combination Therapy Effective in Treating Chemo-Resistant Ovarian Cancer

05/09/2017

JCP Editors

A combination regimen involving standard carboplatin chemotherapy and a novel drug may improve overall survival for more than 50% of women with high-grade serous ovarian cancers, according to research published in...

A...

05/09/2017

Journal of Clinical Pathways

Research in Review

Mutations in CLL Cells May Be Used as Biomarker for Future Relapse

05/09/2017

JCP Editors

Certain mutations in relapsed chronic lymphocytic leukemia (CLL) after targeted therapy have the potential to be used as a biomarker for relapse, according to research published in the Journal of Clinical Oncology...

...

05/09/2017

Journal of Clinical Pathways

Research in Review

New Biomarker Helps Predict PFS in Patients With Type of NSCLC

05/05/2017

JCP Editors

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with crizotinib may experience increased progression-free survival (PFS) with a decrease in a type of circulating tumor cells, according...

...

05/05/2017

Journal of Clinical Pathways

Research in Review

Treatment Better Than Observation for Older Patients With Esophageal Cancer

05/03/2017

JCP Editors

Patients aged 80 years or older with early-stage esophageal cancer who received treatment had an increased 5-year overall survival (OS) compared with those who received no treatment or observation alone,...

...

05/03/2017

Journal of Clinical Pathways

Research in Review

CAR T-Cells Offer Biomarker for Objective Response in Non-Hodgkin Lymphoma

04/28/2017

JCP Editors

The ability of chimeric antigen receptor (CAR) T-cells to perform multiple functions is associated with improved outcomes for patients with advanced non-Hodgkin lymphoma, offering a biomarker for response, according...

The...

04/28/2017

Journal of Clinical Pathways

Research in Review

Serum Marker Helps Predict Response to CAR-T Therapy in Lymphoma

04/28/2017

JCP Editors

Patients with relapsed or refractory lymphoma who achieve durable remission after low-dose conditioning chemotherapy and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tend to have high serum levels of a...

...

04/28/2017

Journal of Clinical Pathways